Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ lives. In this webinar, we will discuss our recent technical advancements in efficient viral vector manufacturing process development. From cell line development, to suspension culture of HEK293 cells, to media optimization and purification process, a series of improvements were implemented to advance our platform development for scalable large-scale manufacturing of viral vectors, including adenoassociated viruses (AAV) and lentiviruses.
Key lessons learned:
– Scalability is important
– Efficient process with high quality and high yield